Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5272029
Max Phase: Preclinical
Molecular Formula: C60H62F3N11O6S2
Molecular Weight: 1154.35
Associated Items:
ID: ALA5272029
Max Phase: Preclinical
Molecular Formula: C60H62F3N11O6S2
Molecular Weight: 1154.35
Associated Items:
Canonical SMILES: Cc1cc([C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC(=O)NCCCN2CCN(c3ccc(C#Cc4ccc(N5C(=S)N(c6ccc(C#N)c(C(F)(F)F)c6)C(=O)C5(C)C)cc4)cn3)CC2)c2ccc(-c3sncc3C)cc2)C(C)C)on1
Standard InChI: InChI=1S/C60H62F3N11O6S2/c1-36(2)53(50-28-38(4)69-80-50)56(78)72-35-46(75)30-49(72)55(77)68-48(41-13-15-42(16-14-41)54-37(3)33-67-82-54)31-52(76)65-22-7-23-70-24-26-71(27-25-70)51-21-12-40(34-66-51)9-8-39-10-18-44(19-11-39)74-58(81)73(57(79)59(74,5)6)45-20-17-43(32-64)47(29-45)60(61,62)63/h10-21,28-29,33-34,36,46,48-49,53,75H,7,22-27,30-31,35H2,1-6H3,(H,65,76)(H,68,77)/t46-,48+,49+,53-/m1/s1
Standard InChI Key: YMKQUXFSWVZULN-TWPSXJLCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1154.35 | Molecular Weight (Monoisotopic): 1153.4278 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, Wang M, Zhao L, Xu T, Chinnaswamy K, Delproposto J, Stuckey J, Wang S.. (2019) Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer., 62 (2): [PMID:30629437] [10.1021/acs.jmedchem.8b01631] |
Source(1):